Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 1
2014 1
2015 1
2016 2
2017 1
2020 3
2021 2
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study.
Chen L, Dai H, Wang J, Wang M, Ma Y, Ma F, Li C, Bai L, Du L, Tang H. Chen L, et al. Ann Transl Med. 2022 Oct;10(20):1125. doi: 10.21037/atm-22-4369. Ann Transl Med. 2022. PMID: 36388832 Free PMC article.
BACKGROUND: Albuvirtide (ABT), a fusion inhibitor against human immunodeficiency virus (HIV) infection, has good efficacy and tolerability for HIV treatment. ...
BACKGROUND: Albuvirtide (ABT), a fusion inhibitor against human immunodeficiency virus (HIV) infection, has good efficacy and tolerab …
Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS.
Liu H, He S, Yang T, Lu C, Yao Y, Zhou R, Yin K, He Y, Cheng J. Liu H, et al. Medicine (Baltimore). 2023 Nov 10;102(45):e35344. doi: 10.1097/MD.0000000000035344. Medicine (Baltimore). 2023. PMID: 37960773 Free PMC article.
Treatment options for hospitalized people living with HIV/AIDS (PLWHA) with opportunistic infections and comorbidities are limited in China. Albuvirtide (ABT), a new peptide drug, is a long-acting HIV fusion inhibitor with limited drug-drug interactions and fast onset time …
Treatment options for hospitalized people living with HIV/AIDS (PLWHA) with opportunistic infections and comorbidities are limited in China. …
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Mu TT, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Zhang YH, Wang H, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Hu M, Liu X, Lu RJ, Hu JH, Sun CC, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H. Su B, et al. J Infect. 2022 Sep;85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. Epub 2022 Jun 1. J Infect. 2022. PMID: 35659547 No abstract available.
Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report.
Tang W, Song XY, Cao J, Liu C, Zheng F. Tang W, et al. AIDS Res Ther. 2023 Aug 28;20(1):60. doi: 10.1186/s12981-023-00560-w. AIDS Res Ther. 2023. PMID: 37641133 Free PMC article.
BACKGROUND: Managing multidrug-resistant (MDR) HIV infections in children is particularly challenging due to the lack of experience with new drugs in the pediatric setting. Second-line albuvirtide (ABT) with an optimized antiretroviral background therapy was approved for a …
BACKGROUND: Managing multidrug-resistant (MDR) HIV infections in children is particularly challenging due to the lack of experience with new …
Peptide-Based HIV Entry Inhibitors.
Pu J, Wang Q, Jiang S. Pu J, et al. Adv Exp Med Biol. 2022;1366:15-26. doi: 10.1007/978-981-16-8702-0_2. Adv Exp Med Biol. 2022. PMID: 35412132
In particular, the peptide-based anti-HIV drugs enfuvirtide and albuvirtide were approved for clinical use by the U.S. FDA and CFDA in 2003 and 2018, respectively. ...
In particular, the peptide-based anti-HIV drugs enfuvirtide and albuvirtide were approved for clinical use by the U.S. FDA and CFDA i …
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Lu RJ, Hu JH, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H; TALENT Study Team. Su B, et al. Chin Med J (Engl). 2020 Nov 25;133(24):2919-2927. doi: 10.1097/CM9.0000000000001273. Chin Med J (Engl). 2020. PMID: 33252379 Free PMC article. Clinical Trial.
BACKGROUND: Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated …
BACKGROUND: Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data fo …
Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China.
Nie J, Sun F, He X, Liu J, Wang M, Li C, Gu S, Chen Z, Li Y, Chen Y. Nie J, et al. Infect Dis Ther. 2021 Dec;10(4):2611-2623. doi: 10.1007/s40121-021-00540-5. Epub 2021 Sep 29. Infect Dis Ther. 2021. PMID: 34586592 Free PMC article.
The present study aimed to explore the safety, tolerability, and adherence of regimens containing albuvirtide (ABT) compared with recommended non-STR antiretrovirals for HIV PEP. ...
The present study aimed to explore the safety, tolerability, and adherence of regimens containing albuvirtide (ABT) compared with rec …
Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.
Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, Peng H, Wang X, Lu R, Wang C, Xie D, Wu H. Zhang H, et al. AIDS Res Ther. 2016 Feb 10;13:8. doi: 10.1186/s12981-016-0091-1. eCollection 2016. AIDS Res Ther. 2016. PMID: 26865854 Free PMC article. Clinical Trial.
BACKGROUND: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11-12 days in human. ...
BACKGROUND: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the effic …
Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y. Chong H, et al. PLoS One. 2012;7(3):e32599. doi: 10.1371/journal.pone.0032599. Epub 2012 Mar 5. PLoS One. 2012. PMID: 22403678 Free PMC article.
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. ...
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to ser …
Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.
Yang W, Xiao Q, Wang D, Yao C, Yang J. Yang W, et al. Xenobiotica. 2017 Feb;47(2):133-143. doi: 10.3109/00498254.2016.1166532. Epub 2016 Apr 6. Xenobiotica. 2017. PMID: 27052428
Because albuvirtide requires a long period to achieve steady state, and extended monotherapy may lead to early resistance, it is unethical to take albuvirtide alone to achieve steady state. Therefore, a population pharmacokinetic model was developed to predict stead …
Because albuvirtide requires a long period to achieve steady state, and extended monotherapy may lead to early resistance, it is unet …
19 results